Head to Head Analysis: PainReform (NASDAQ:PRFX) and Vaxart (OTCMKTS:VXRT)

Vaxart (OTCMKTS:VXRT) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.

Earnings & Valuation

This table compares Vaxart and PainReform”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$237.26 million	0.42	$16.33 million	$0.16	2.56
PainReform	$20,000.00	32.19	-$5.02 million	($736.66)	-0.00

Vaxart has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

18.0% of Vaxart shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 2.8% of Vaxart shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Vaxart has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, PainReform has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Profitability

This table compares Vaxart and PainReform’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxart	15.88%	53.04%	20.85%
PainReform	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Vaxart and PainReform, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0	1	0	0	2.00
PainReform	1	0	0	0	1.00

Summary

Vaxart beats PainReform on 8 of the 12 factors compared between the two stocks.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.